Clinical trials: Tumor Gastric
Peritoneal Carcinomatosis
Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors
Single center, open label, phase I-II, non-randomized, two-cohort, repeated single dose study to explore the feasibility, efficacy, safety, and Overall Response Rate (ORR) of oxaliplatin, or cisplatin and doxorubicin when given…
- Trial name
- PI-CaP (NCT02604784)
- Testing
- Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose, Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose
- Where
- Italy
- Volunteers
- 105 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Gastric Cancer, Adjuvant Chemotherapy, XO
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
multicenter, open label, randomaized, phase III The role of post surgery adjuvant chemotherapy is becoming more and more important in AGC (advance gastric cancer).
- Trial name
- NCT01935778
- Testing
- Docetaxel and capecitabine and oxaliplatin, capecitabine and oxaliplatin
- Where
- South Korea
- Volunteers
- 286 people
- Sponsor
- Asan Medical Center
Peritoneal Diseases
ERAS® Guidelines Validation of CRS With or Without HIPEC
Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative…
- Trial name
- NCT05185791
- Testing
- Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 288 people
- Sponsor
- Hospices Civils de Lyon
Gastric Cancer, Precancerous Lesion of Digestive Tract
The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
ECDNA is almost non-existent in normal cells, but exists in nearly half of human cancer cells, indicating that studying such abnormal DNA is of great significance for our understanding of tumor formation and evolution.
- Conditions
- Gastric Cancer, Precancerous Lesion of Digestive Tract, Extrachromosomal DNA
- Trial name
- NCT05956847
- Testing
- gastroscopy
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Gastric Cancer
Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery
The patients will be divided into two groups: in the first group the patient will be submitted to prophylactic cholecystectomy during standard surgery for curable gastric cancer (subtotal or total gastrectomy), while in the…
- Trial name
- CHOLEGAS (NCT00757640)
- Testing
- cholecystectomy
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Italian Research Group for Gastric Cancer
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
This study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and SOX of neoadjuvant treatment for resectable locally advanced gastric…
- Trial name
- NCT06693128
- Testing
- Camrelizumab, Apatinib, S-1, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- Ruijin Hospital
HER2-positive Gastric Cancer
ctDNA Screening in Advanced HER2 Positive Gastric Cancer
To identify molecular biomarker panel correlating with efficacy of trastuzuamb in advanced HER2 positive gastric cancer patients.
- Trial name
- NCT04520295
- Testing
- ctDNA screening
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05365581
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 46 sites in United States, China and 6 more
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
The aim of this phase I-II study is to evaluate the efficacy and toxicity of PRRT with 177Lu-DOTATATE (Lu-PRRT) associated to metronomic chemotherapy with Capecitabine in patients affected by aggressive FDG-positive…
- Trial name
- LuX (NCT02736500)
- Testing
- 28 GBq 177Lu-DOTATATE, 22 GBq 177Lu-DOTATATE
- Where
- 2 sites in Italy
- Volunteers
- 39 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Stomach Neoplasms
Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Stomach Neoplasms.
- Trial name
- IRE (NCT02430636)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Stomach Neoplasm
Use of Blood Biomarkers to Predict Gastric Cancer Risk
This study aims to develop a cost-effective screening strategy for the Singapore population by targeted screening of people who have a high risk of stomach cancer, in order to detect early signs of the disease at a stage that can…
- Trial name
- NCT04329299
- Testing
- blood-based biomarkers analyses
- Where
- 2 sites in Singapore
- Volunteers
- 6,862 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Advanced Gastrointestinal Tumors
Study of Minnelide™ in Patients With Advanced GI Tumors
The primary objective of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™ and to establish the dose of Minnelide™ recommended for future phase 2 protocol
- Trial name
- NCT01927965
- Testing
- Minnelide™ 001
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Minneamrita Therapeutics LLC
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Feasibility, Complications
Endoscopic Full-thickness Resection of Gastric Subepithelial Tumors With the gFTRD
Subepithelial gastric tumors are rare and usually detected incidentally. Most subepithelial tumors (SET) are benign but up to 13% of all lesions can be malignant.
- Trial name
- RESET (NCT03096236)
- Testing
- EFTR
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Kliniken Ludwigsburg-Bietigheim gGmbH
Advanced Cancer, Breast Cancer
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
There will be two phase II cohorts for pembro plus trastuzumab: one cohort will be for patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will be for patients with HER2 overexpressing…
- Conditions
- Advanced Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- PembroMab (NCT02318901)
- Testing
- Pembrolizumab, Trastuzumab, ado-trastuzumab emtansine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Western Regional Medical Center
Metastatic or Recurrent Gastric Adenocarcinoma, Her-2 Positive Gastric Cancer
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
This is an open-label, multicentre, prospective phase II trial designed to evaluate the efficacy and safety of trastuzumab in combination with capecitabine and oxaliplatin as first-line therapy in patients with recurrent and/or…
- Trial name
- NCT01396707
- Testing
- Herceptin+XELOX
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Asan Medical Center
Advanced Solid Tumors
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency.
- Trial name
- NCT06183736
- Testing
- CVL237 tablets
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Gastritis, Atrophic, Stomach Neoplasms
Gastropanel for Gastric Atrophy and Cancer Risk Assessment
Background: Atrophic gastritis (AG) is the single most important precursor condition for gastric cancer (GC) known so far. H. pylori infection is the most important causative agent of gastritis, and subsequent AG.
- Trial name
- NCT02114411
- Testing
- GastroPanel test, Gastroscopy
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Biohit Healthcare Ltd
Stomach Cancer, Esophageal Cancer
Comparison of Standard of Care or Treatment on Protocol
Patient will choose to either receive the standard of care according to National Comprehensive Cancer Network (NCCN) or approved guidelines for their condition or to be treated according to one arm of the protocol that they could…
- Conditions
- Stomach Cancer, Esophageal Cancer, Bladder Cancer, Skin Cancer
- Trial name
- NCT01010334
- Testing
- standard of care
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- New Mexico Cancer Research Alliance
Gastric Cancer, Atrophic Gastritis
Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
The study is aimed to determine the potential of volatile marker testing for gastric cancer screening. The study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing…
- Conditions
- Gastric Cancer, Atrophic Gastritis, Gastric Dysplasia, H.Pylori Infection
- Trial name
- VOGAS (NCT04022109)
- Testing
- Breath sampling for VOC detection, Surgery material collection for VOC headspace analysis, Upper endoscopy
- Where
- 5 sites in Brazil, Chile and 3 more
- Volunteers
- 5,000 people
- Sponsor
- University of Latvia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.